Mount Sinai Researchers Uncover Innovative Approach to Treating Aggressive Lung Cancer

Mount Sin Researchers Unveil New Approach to Treating Small Cell Lung Cancer

Icahn School of Medicine at Mount Sin researchers have made significant strides in tackling small cell lung cancer SCLC, one of the most aggressive forms of lung cancer, with a novel study published in Science Advances on September 27th. The groundbreaking research titled “ATR Inhibition Activates Cancer Cell cGASSTING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung Cancer” introduces an innovative strategy that holds promising prospects for SCLC patients.

Small cell lung cancer affects around 10 to 15 of the total number of lung cancer cases in the United States, with approximately 30,000 to 35,000 new cases diagnosed annually. Unfortunately, by the time most patients are diagnosed, the disease has often spread extensively, making treatment particularly challenging. Current therapies, including chemotherapy and immunotherapy, offer only temporary relief, resulting in a five-year survival rate of less than 10.

Dr. Triparna Sen, Associate Professor of Oncological Sciences at Icahn Mount Sin and Director of the Lung Cancer PDX Platform, states: We have focused on ATR ataxia telangiectasia and Rad3-related protein, playing a key role in DNA repr within cancer cells. By inhibiting this enzyme, we weaken these cancer cells' defenses and enhance their vulnerability to treatments while simultaneously boosting the immune system's capability to target them.

This pioneering study explores the effects of berzosertib M6620VX970, an experimental drug combined with topotecan for relapsed SCLC patients. Our findings suggest that this combination could be particularly effective, especially for those whose cancer has returned after initial treatment, Sen emphasizes.

The research reveals how ATR inhibition activates the cGASSTING-interferon pathway within cancer cells, a process that promotes anti-tumor immunity by enhancing immune response agnst cancer cells. By unlocking this mechanism and leveraging it to the patient's advantage, we m to provide more effective therapy options for SCLC patients, Sen further explns.

With this groundbreaking research, Mount Sin continues its commitment towards developing innovative therapies and improving survival rates for patients battling lung cancer, a cause that disproportionately impacts many communities worldwide. s not only advance our understanding of ATR inhibition but also offer hope for future treatment strategies agnst SCLC through immunotherapy approaches.

For more information on the study or to learn about ongoing clinical trials at Icahn School of Medicine at Mount Sin, please visit https:www.mountsin.org.

This press release is provided by Icahn School of Medicine at Mount Sin and share this significant development in cancer research with a global audience. Should you have further questions or inquiries, we welcome your contact through our media page.

[email protected] 212-241-9200 Fax: 212-241-6512

In this story:

Triparna Sen, PhD

Oncological Sciences at Icahn School of Medicine
This article is reproduced from: https://www.mountsinai.org/about/newsroom/2024/new-mount-sinai-research-brings-hope-for-small-cell-lung-cancer-patients

Please indicate when reprinting from: https://www.81le.com/Tumor_Cancer/Mount_Sin_lung_cancer_research.html